BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 7510495)

  • 1. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
    Del Favero A; Roila F; Tonato M
    Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research on antiemetics: an Italian model of success].
    Roila F
    Tumori; 1998; 84(1 Suppl):S3-11. PubMed ID: 9617377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chemotherapy-induced emesis: the state of the art.
    Roila F; Tonato M; Del Favero A
    Dig Dis; 1993; 11(6):343-53. PubMed ID: 8306491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
    Malik I; Moid I; Khan Z; Hussain M
    Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
    Ann Oncol; 1998 Aug; 9(8):811-9. PubMed ID: 9789602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
    Hesketh PJ
    Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetics revisited.
    Roila F; Del Favero A
    Curr Opin Oncol; 1997 Jul; 9(4):321-6. PubMed ID: 9251881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of chemotherapy-induced delayed emesis.
    Tavorath R; Hesketh PJ
    Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
    Tonato M; Roila F; Del Favero A; Ballatori E
    Support Care Cancer; 1994 May; 2(3):150-60. PubMed ID: 8032700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.